Full-Time
Posted on 2/1/2025
Develops and manufactures vaccines and medicines
$242k - $403.4kAnnually
Expert
No H1B Sponsorship
Cambridge, MA, USA
Relocation eligible
You match the following Pfizer's candidate preferences
Employers are more likely to interview you if you match these preferences:
Pfizer focuses on creating and producing healthcare products, particularly medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then manufactured and sold globally. Pfizer's products include vaccines, cancer treatments, and other specialized medications. A key aspect of Pfizer's operations is its collaboration with BioNTech to develop a vaccine for COVID-19, showcasing its role in addressing public health challenges. Unlike many competitors, Pfizer emphasizes not only the development of new drugs but also the distribution of vaccines to underserved communities. The company's goal is to enhance global health by expanding its range of effective treatments and ensuring access to its products.
Company Size
10,001+
Company Stage
IPO
Total Funding
$3.8B
Headquarters
New York City, New York
Founded
1849
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The
The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.
The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is
CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from Our
Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Ac
Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical...
TIAA Trust National Association invests $17.55 million in Pfizer Inc. (NYSE:PFE).
Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management &a
11/10/2023 Nota de prensa GOMAB, PARTICIPADA DE ASABYS, CIERRA UNA SERIES C DE $100M CON FIDELITY, EQT LIFE SCIENCES, CANAAN, KKR, ASABYS Y PFIZER Agomab Therapeutics NV(‘Agomab’) ha anunciado hoy el cierre de una ronda de financiación Serie C de 100 millones de dólares liderada por Fidelity Management & Research Company (FMR), con la participación…
CellCentric, a Cambridge, UK- and and Manchester, UK-based biotechnology company, received a $25M strategic investment from Pfizer.Pfizer will support the company with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific haematological malignancies, through its Pfizer Ignite offering.Led by CEO Will West, CellCentric focuses on twin acetyl transferase proteins, p300 and CBP, that act as transcription co-activation factors, and that drive the expression of genes important in cancer progression. The company, which has investigated over 50 epigenetic-related targets as new ways to treat disease, and specifically cancer, was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of epigenetics to deliver new treatments. In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.Inobrodib works by binding to a specific part of proteins p300 and CBP (bromodomain). It is highly selective and does not impact similar pockets on other proteins. Through this action inobrodib reduces the expression of key cancer drivers: IRF4, MYC, and the androgen receptor (AR and its variants).In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.As part of the collaboration, Astrid Ruefli-Brasse, Vice President, Tumour Biology, Pfizer Worldwide Research Development, will join CellCentric’s Scientific Advisory Board and Sriram Krishnaswami, Vice President and Development Head, Multiple Myeloma, Pfizer Global Product Development, will serve as an advisor to CellCentric.FinSMEs23/07/2023